However, in the aggressively growing tumor cell line, receptor activity could be protected by the upregulation of the neutral ligand Cxcl5 (32-fold relative to vGPCR-3T3) that competes with the antagonist CXCL12 for receptor binding. The gene discussed is CXCL12; the disease is neoplasm.